EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer

Journal of Biomedical Nanotechnology

Volumn 7, Issue 1, 2011, Pages 137-138

  Aggarwal, Sahil ^a   Yadav, Sachin ^a   Gupta, Swati ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Adenocarcinoma; Anti EGFR monoclonal antibody; Gemcitabine; PLGA nanoparticles

Indexed keywords

ADENOCARCINOMA; ANTI-EGFR; COVALENT COUPLINGS; DRUG CARRIER SYSTEMS; GEMCITABINE; GLUTARALDEHYDES; IN-VITRO; MONOCLONAL ANTIBODIES (MAB); PANCREATIC CANCERS; PANCREATIC CELLS; PLGA NANOPARTICLES; POLYMERIC NANOPARTICLES; TARGETED CHEMOTHERAPY;

ALDEHYDES; CHEMOTHERAPY; DISEASES; MONOCLONAL ANTIBODIES;

NANOPARTICLES;

EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GLUTARALDEHYDE; NANOPARTICLE; POLYGLACTIN; DEOXYCYTIDINE; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; LACTIC ACID; MONOCLONAL ANTIBODY; NANOCAPSULE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; PANCREAS CANCER; PANCREAS CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG FORMULATION; METABOLISM; METHODOLOGY; PANCREAS TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG COMPOUNDING; HUMANS; LACTIC ACID; NANOCAPSULES; PANCREATIC NEOPLASMS; POLYGLYCOLIC ACID; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 79957701112     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1238     Document Type: Article

References (4)

1. A. C. Berger, I. M. Meszoely, E. A. Ross, J. C. Watson, and J. P. Hoffman, Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with respectable pancreatic adenocarcinoma. Ann. Surg. Oncol. 11, 644 (2004).
2. C. R. Patra, R. Bhattacharya, E. Wang, A. Katarya, J. S. Lau, S. Dutta, M. Muders, S. Wang, S. A. Buhrow, S. L. Safgren, M. J. Yaszemski, J. M. Reid, M. M. Ames, P. Mukherjee, and D. Mukhopadhyay, Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Can. Res. 68, 1970 (2008).
3. K. A. Avgoustakis, Z. Beletsi, P. Panagi, A. G. Klepetsanis, and D. S. Karydas, Ithakissios, PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Cont. Rel. 79, 123 (2002).
4. J. Cheng, B. A. Teply, I. Sherifi, J. Sung, G. Luther, F. X. Gu, E. L. Nissenbaum, A. F. R. Moreno, R. Langer, and O. C. Farokhzad, Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869 (2007).